newsfilter
← Latest News
GlobeNewswire·

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug